Dose escalation of tolinapant (ASTX660) in combination with standard radical chemoradiotherapy in cervical cancer: A study protocol for a phase 1b TiTE-CRM clinical trial (CRAIN) in UK secondary care centres

Cervical cancer is the fourth most common cancer in women, with an estimated 342,000 deaths worldwide in 2020. Current standard of care in the UK for locally advanced cervical cancer is concurrent chemoradiotherapy with weekly cisplatin, yet 5-year overall survival rates are only 65% with a distant relapse rate of 50%.